- Home
- LITS vs MGNX Comparison
LITS vs MGNX Comparison
Compare LITS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITS
- MGNX
- Stock Information
- Founded
- LITS 2000
- MGNX 2000
- Country
- LITS United States
- MGNX United States
- Employees
- LITS N/A
- MGNX N/A
- Industry
- LITS Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- LITS Health Care
- MGNX Health Care
- Exchange
- LITS Nasdaq
- MGNX Nasdaq
- Market Cap
- LITS 96.2M
- MGNX 99.7M
- IPO Year
- LITS N/A
- MGNX 2013
- Fundamental
- Price
- LITS $2.43
- MGNX $1.72
- Analyst Decision
- LITS
- MGNX Hold
- Analyst Count
- LITS 0
- MGNX 6
- Target Price
- LITS N/A
- MGNX $3.20
- AVG Volume (30 Days)
- LITS 1.3M
- MGNX 630.9K
- Earning Date
- LITS 11-11-2025
- MGNX 11-04-2025
- Dividend Yield
- LITS N/A
- MGNX N/A
- EPS Growth
- LITS N/A
- MGNX N/A
- EPS
- LITS N/A
- MGNX N/A
- Revenue
- LITS N/A
- MGNX $165,495,000.00
- Revenue This Year
- LITS N/A
- MGNX N/A
- Revenue Next Year
- LITS N/A
- MGNX N/A
- P/E Ratio
- LITS N/A
- MGNX N/A
- Revenue Growth
- LITS N/A
- MGNX 303.47
- 52 Week Low
- LITS $1.46
- MGNX $0.99
- 52 Week High
- LITS $9.00
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- LITS N/A
- MGNX 50.98
- Support Level
- LITS N/A
- MGNX $1.66
- Resistance Level
- LITS N/A
- MGNX $1.83
- Average True Range (ATR)
- LITS 0.00
- MGNX 0.12
- MACD
- LITS 0.00
- MGNX 0.00
- Stochastic Oscillator
- LITS 0.00
- MGNX 53.70
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.